158 related articles for article (PubMed ID: 9707312)
1. In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori.
Alarcón T; Domingo D; Sánchez I; Sanz JC; Martínez MJ; López-Brea M
Eur J Clin Microbiol Infect Dis; 1998 Apr; 17(4):275-7. PubMed ID: 9707312
[TBL] [Abstract][Full Text] [Related]
2. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine.
van Herwaarden MA; Samsom M; van Nispen CH; Mulder PG; Smout AJ
Aliment Pharmacol Ther; 1999 Jun; 13(6):731-40. PubMed ID: 10383501
[TBL] [Abstract][Full Text] [Related]
3. Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection.
Bravo LE; Realpe JL; Campo C; Mera R; Correa P
Am J Gastroenterol; 1999 Sep; 94(9):2380-3. PubMed ID: 10483995
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal activity of lansoprazole and omeprazole against Helicobacter pylori in vitro.
Vogt K; Hahn H
Arzneimittelforschung; 1998 Jun; 48(6):694-7. PubMed ID: 9689430
[TBL] [Abstract][Full Text] [Related]
5. Bacteriostatic and bactericidal activity of ranitidine bismuth citrate in Helicobacter pylori clinical isolates.
Alarcón T; Domingo D; Prieto N; López-Brea M
Rev Esp Quimioter; 1999 Mar; 12(1):64-8. PubMed ID: 10209056
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.
Nakao M; Tada M; Tsuchimori K; Uekata M
Eur J Clin Microbiol Infect Dis; 1995 May; 14(5):391-9. PubMed ID: 7556227
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of Helicobacter pylori to antimicrobial agents: effect of ebrotidine and ranitidine.
Piotrowski J; Piotrowski E; Slomiany A; Slomiany BL
J Physiol Pharmacol; 1995 Dec; 46(4):463-9. PubMed ID: 8770790
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.
Nakao M
J Clin Gastroenterol; 1995; 20 Suppl 1():S32-7. PubMed ID: 7673612
[TBL] [Abstract][Full Text] [Related]
9. Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study.
Malizia T; Tejada M; Marchetti F; Favini P; Pizzarelli G; Campa M; Senesi S
J Antimicrob Chemother; 1998 Mar; 41 Suppl B():29-35. PubMed ID: 9579710
[TBL] [Abstract][Full Text] [Related]
10. In vitro anti-Helicobacter pylori activity of ebrotidine.
Palacín C; Tarragó C; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):471-4. PubMed ID: 9205746
[TBL] [Abstract][Full Text] [Related]
11. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.
Iwahi T; Satoh H; Nakao M; Iwasaki T; Yamazaki T; Kubo K; Tamura T; Imada A
Antimicrob Agents Chemother; 1991 Mar; 35(3):490-6. PubMed ID: 2039199
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori.
Nakao M; Malfertheiner P
Helicobacter; 1998 Mar; 3(1):21-7. PubMed ID: 9546114
[TBL] [Abstract][Full Text] [Related]
13. Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication.
Spadaccini A; De Fanis C; Sciampa G; Russo L; Silla M; Pantaleone U; Di Virgilio M; Pizzicanella G
Aliment Pharmacol Ther; 1998 Oct; 12(10):997-1001. PubMed ID: 9798805
[TBL] [Abstract][Full Text] [Related]
14. [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
Buzás György M; Székely E; Illyés G; Széles I
Orv Hetil; 2000 Jul; 141(31):1711-4. PubMed ID: 10976194
[TBL] [Abstract][Full Text] [Related]
15. Study of the combination of ranitidine bismuth citrate and metronidazole against metronidazole-resistant Helicobacter pylori clinical isolates.
López-Brea M; Domingo D; Sánchez I; Prieto N; Alarcón T
J Antimicrob Chemother; 1998 Sep; 42(3):309-14. PubMed ID: 9786470
[TBL] [Abstract][Full Text] [Related]
16. Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro.
Midolo PD; Turnidge JD; Lambert JR; Bell JM
Antimicrob Agents Chemother; 1996 Jun; 40(6):1531-3. PubMed ID: 8726032
[TBL] [Abstract][Full Text] [Related]
17. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Helicobacter pylori urease activity by ebrotidine.
Piotrowski J; Slomiany A; Slomiany BL
Biochem Mol Biol Int; 1995 Oct; 37(2):247-53. PubMed ID: 8673007
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori.
Alarcón T; Domingo D; Sánchez I; Díaz de Rojas F; López-Brea M
Eur J Clin Microbiol Infect Dis; 1996 Dec; 15(12):937-40. PubMed ID: 9031877
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory activities of lansoprazole against respiration in Helicobacter pylori.
Nagata K; Sone N; Tamura T
Antimicrob Agents Chemother; 2001 May; 45(5):1522-7. PubMed ID: 11302821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
